Keefe, Bruyette & Woods Downgrades Pennant Park Investment to Market Perform, Lowers Price Target to $5.5
Keefe, Bruyette & Woods analyst Ryan Lynch downgrades Pennant Park Investment (NYSE:PNNT) from Outperform to Market Perform and lowers the price target from $7 to $5.5.
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 402 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 361 companies set new 52-week lows.
Recap: Pennant Park Investment Q3 Earnings
Pennant Park Investment (NYSE:PNNT) reported its Q3 earnings results on Wednesday, August 3, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Raymond James Maintains Outperform on Pennant Park Investment, Raises Price Target to $9
Raymond James analyst Robert Dodd maintains Pennant Park Investment (NASDAQ:PNNT) with a Outperform and raises the price target from $8 to $9.
Pennant Park Investment Q1 EPS $0.19 Beats $0.14 Estimate
Pennant Park Investment (NASDAQ:PNNT) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.14 by 35.71 percent. This is a 58.33 percent increase over earnings of $0.12 per share